Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,249
datasets available to search
ShareScore release 0.9.0
Dataset results
1,249 results for “Hemorrhage”
Comparison of Primary and Secondary Prevention of Postpartum Hemorrhage at the Community Level in Egypt
ClinicalTrials.gov study NCT02226588. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Genomic and immunogenic changes of Piscine novirhabdovirus (Viral hemorrhagic septicemia virus) over its evolutionary history in the Laurentian Great Lakes
Open the record for dataset details and reuse information.
Data from: Vegetarian diet and incidence of total, ischemic and hemorrhagic stroke in two cohorts in Taiwan
Open the record for dataset details and reuse information.
Rare missense functional variants at COL4A1 and COL4A2 in sporadic intracerebral hemorrhage
Open the record for dataset details and reuse information.
Shock Index for Predicting Adverse Obstetric Hemorrhage Outcome
Open the record for dataset details and reuse information.
Data from: Race/Ethnicity Influences Outcomes in Young Adults with Intracerebral Hemorrhage
Objectives: We investigated the predictors of functional outcome in young patients enrolled in a multi-ethnic study of intracerebral hemorrhage (ICH). Methods: The Ethnic/Racial Variations in Intracerebral Hemorrhage (ERICH) study is a prospective multi-center study of ICH among adult (age ≥18 years) non-Hispanic whites, non-Hispanic blacks, and Hispanics. The study recruited 1000 participants per racial/ethnic group. The present study utilized the subset of ERICH cases aged <50 years with supratentorial ICH. Functional outcome was ascertained using the modified Rankin Scale (mRS) at 3 months. Logistic regression was used to identify factors associated with poor outcome (mRS 4–6), and analyses were compared by race/ethnicity to identify differences across these groups. Results: Of the 3000 ICH cases enrolled in ERICH, 418 were studied (mean age 43 years, 69% male), of which 48 (12%) were white, 173 (41%) were black, and 197 (47%) were Hispanic. For supratentorial ICH, blacks (odds ratio [OR] 0.42, p=0.046) and Hispanics (OR 0.34, p=0.01) had better outcomes than whites after adjustment for other factors associated with poor outcome: age, baseline disability, admission blood pressure, admission Glasgow Coma Scale score, ICH volume, deep ICH location, and intraventricular extension. Conclusions: In young patients with supratentorial ICH, black and Hispanic race/ethnicity is associated with better functional outcomes, compared with white race. Additional studies are needed to identify the biological and social mediators of this association.
Data from: Clinical complications and outcomes of angiographically negative subarachnoid hemorrhage
Objective: To define the in-hospital course, complications, short- and long-term functional outcomes of patients with angiographically negative subarachnoid hemorrhage (anSAH), particularly those with aneurysmal-pattern anSAH (aanSAH). Methods: Retrospective cohort study of patients with aneurysmal subarachnoid hemorrhage (aSAH), aanSAH and perimesencephalic-pattern anSAH (panSAH) treated at a single tertiary referral center between January 2006 and April 2018. Ninety-nine patients with anSAH (33 aanSAH and 66 panSAH) and 464 patients with aSAH were included in this study. Outcomes included symptomatic hydrocephalus requiring CSF drainage, need for ventriculoperitoneal shunt (VPS), radiographic vasospasm, delayed cerebral ischemia (DCI), radiographic infarction, disability level within one year of ictus and at last clinical follow-up as defined by modified Rankin Scale (mRS). Results: Patients with aanSAH and panSAH had similar rates of DCI and radiologic infarction, and patients with aanSAH had significantly lower rates compared to aSAH (P≤0.018). Patients with aanSAH were more likely than those with panSAH to require temporary CSF diversion and VPS (P≤0.03), with similar rates to those seen in aSAH. Only one patient with anSAH died in the hospital. Compared to those with aSAH, patients with aanSAH were significantly less likely to have a poor functional outcome within one year of ictus (OR 0.26, 95% CI 0.090 – 0.75) and at last follow-up (HR 0.30, 95% CI 0.19 – 0.49, P=0.002). Conclusions: DCI is very uncommon in anSAH, but patients with aanSAH have a similar need for short- and long-term CSF diversion to patients with aSAH. Nevertheless, patients with aanSAH have significantly better short- and long-term outcomes.
Hemoglobin Metabolism after Hemorrhagic Stroke
<p>Raw data from research on hemoglobin metabolism in the pathophysiology of hemorrhagic stroke</p>
Microbleeds, cerebral hemorrhage, and functional outcome after endovascular thrombectomy
<p><b>Objective</b>—To determine <span>whether the presence, number, and distribution of cerebral microbleeds (CMBs) on </span>pretreatment MRI <span>scans are associated with an increased risk of intracerebral hemorrhage (ICH) or poor functional outcome </span>following <span>endovascular thrombectomy (EVT)</span> for <span>acute ischemic stroke (AIS).</span></p> <p><b>Methods</b>—We analyzed prospectively collected data of consecutive patients treated by <span>EVT</span> for AIS, in a comprehensive stroke center where MRI is the first-line pretreatment imaging. Neuroradiologists blinded to clinical data rated CMBs on T2* sequence using a validated scale. <span>We investigated associations of pre-treatment CMB presence, burden (1, 2–4, and ≥5), and presumed pathogenesis with ICH and poor 3-month functional outcome (modified Rankin score >2)</span>.</p> <p><b>Results</b>—Among 513 patients, <span>281 (54.8%) had a poor outcome</span> and 89 (17.3%) had ≥1 CMBs. <span>A total of 190 (37%) patients experienced ICH, in which 66 (12.9%) were symptomatic. </span>CMB burden was associated with worse outcome in a univariable analysis (odds ratio [OR], 1.18; 95% confidence interval [CI], 1.03–1.36 per 1-CMB increase; P=0.02), but significance was lost after adjustment for age, sex, baseline stroke severity, hypertension, <span>diabetes mellitus</span>, atrial fibrillation, prior antithrombotic medication, intravenous thrombolysis, and reperfusion status (OR, 1.05; 95% CI, 0.92–1.20 per 1-CMB increase; P=0.50). Results remained nonsignificant when taking into account CMB location or presumed underlying vasculopathy. CMB presence, burden, location, nor presumed underlying vasculopathy was independently associated with ICH.</p> <p><b>Conclusions</b>—Poor outcome or ICH was not associated with CMB presence or burden on pre–EVT MRI after adjustment for confounding factors. Excluding such patients from reperfusion therapies is unwarranted.</p>
Data from: Association between aspirin dose and subarachnoid hemorrhage from saccular aneurysms: a case-control study
Objective: We aimed to determine the association between ruptured saccular aneurysms and aspirin use/aspirin dose. Methods: 4,701 patients who were diagnosed at the Massachusetts General Hospital and Brigham and Women's Hospital between 1990 and 2016 with 6,411 unruptured and ruptured saccular intracranial aneurysms were evaluated. Univariable and multivariable logistic regression analyses were performed to determine the association between aSAH and aspirin use, including aspirin dose. Inverse probability weighting using propensity scores was used to adjust for potential differences in baseline characteristics between cases and controls. Additional analyses were performed to examine the association of aspirin use and re-rupture prior to treatment. Results: In multivariate analysis with propensity score weighting, aspirin use (OR 0.60, 95% CI 0.45-0.80) was significantly associated with decreased risk of ruptured intracranial aneurysms. There was a significant inverse dose-response relationship between aspirin dose and aneurysmal subarachnoid hemorrhage (OR 0.65, 95% CI 0.53-0.81). In contrast, there was a significant association between aspirin use and increased risk of re-rupture prior to treatment (OR 8.15, 95% CI 2.22-30.0). Conclusions: In this large case-control study, aspirin therapy at diagnosis was associated with a significantly decreased risk of subarachnoid hemorrhage, with an inverse dose-response relationship among aspirin users. However, once rupture has occurred, aspirin is associated with an increased risk of re-rupture prior to treatment.
Raw data for the article: Extracorporeal Life Support in Hemorrhagic Conditions: A Systematic Review
<p>Extracorporeal life support (ECLS) is indicated in refractory acute respiratory or cardiac failure. According to the need for anticoagulation, bleeding conditions (e.g., in trauma, pulmonary bleeding) have been considered a contraindication for the use of ECLS. However, there is increasing evidence for improved outcomes after ECLS support in hemorrhagic patients based on the benefits of hemodynamic support outweighing the increased risk of bleeding. We conducted a systematic literature search according to the PRISMA guidelines and reviewed publications describing ECLS support in hemorrhagic conditions. Seventy-four case reports, four case series, seven retrospective database observational studies, and one preliminary result of an ongoing study were reviewed. In total, 181 patients were identified in total of 86 manuscripts. The reports included patients suffering from bleeding caused by pulmonary hemorrhage (n = 53), trauma (n = 96), postpulmonary endarterectomy (n = 13), tracheal bleeding (n = 1), postpartum or cesarean delivery (n = 11), and intracranial hemorrhage (n = 7). Lower targeted titration of heparin infusion, heparin-free ECLS until coagulation is normalized, clamping of the endotracheal tube, and other ad hoc possibilities represent potential beneficial maneuvers in such conditions. Once the patient is cannulated and circulation restored, bleeding control surgery is performed for stabilization if indicated. The use of ECLS for temporary circulatory or respiratory support in critical patients with refractory hemorrhagic shock appears feasible considering tailored ECMO management strategies. Further investigation is needed to better elucidate the patient selection and ECLS management approaches.</p>
Risk of hemorrhagic and ischemic stroke in patients with Alzheimer disease: A synthesis of the literature
<span><span><span><span><span><span><span><span><span><span>Objective </span></span></span></span></span></span></span></span></span></span> <p><span><span><span><span><span><span><span><span><span><span>To assess the risk of hemorrhagic and ischemic stroke in patients with Alzheimer disease (AD) compared to non-AD subjects with similar risk profiles.</span></span></span></span></span></span></span></span></span></span></p> <span><span><span><span><span><span><span><span><span><span>Methods </span></span></span></span></span></span></span></span></span></span> <p><span><span><span><span><span><span><span><span><span><span>A search was conducted on Embase and Medline for reports published up to September 26, 2018. Studies were included if they: 1) assessed incidence of stroke in patients diagnosed with </span></span></span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span><span><span>AD; 2) included patients with no history of stroke; and 3) reported outcomes by stroke subtype. The main outcome was relative risk of ischemic or hemorrhagic stroke. Further, the rate of stroke occurrence per 1000 person-years was assessed. A random effects meta-analysis was undertaken. The risk of bias in included studies was assessed in terms of selection, comparability and outcome.</span></span></span></span></span></span></span></span></span></span></p> <span><span><span><span><span><span><span><span><span><span>Results </span></span></span></span></span></span></span></span></span></span> <p><span><span><span><span><span><span><span><span><span><span>3,605 studies were screened in the title and abstract phase after removing duplicates, and 88 eligible studies were screened for full text. Eight studies met the inclusion criteria representing 121,719 subjects (AD=73,044; non-AD=48,675). Five studies were included in the relative risk analysis, among which four studies applied formal matching criteria of 44,544 AD and 44,660 non-AD subjects. The included studies were based on nation-wide registries from Finland, Sweden, Taiwan (2), UK (2), one clinic-based study from the Netherlands and one US population-based cohort.</span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span>Among AD patients, the incidence rate of hemorrhagic stroke was 3.41/1000-person years (95% </span></span></span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span><span><span>CI 2.70, 4.32) and 2.23 (95% CI 1.72, 2.88) among AD-cases and non-AD controls respectively. </span></span></span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span><span><span>This is in contrast to 13.98 (95% CI 9.86, 19.81) and 12.12 (95% CI 7.55, 19.46) for ischemic stroke among AD-cases and non-AD controls respectively. Compared to non-AD subjects with similar risk profiles, AD patients had a relative risk of 1.42 (95% CI 1.23, 1.64) for hemorrhagic stroke and 1.15 (95% CI 0.89, 1.48) for ischemic stroke. </span></span></span></span></span></span></span></span></span></span></p> <span><span><span><span><span><span><span><span><span><span> Conclusion </span></span></span></span></span></span></span></span></span></span> <p><span><span><span><span><span><span><span><span><span><span>Compared to non-AD subjects with similar risk profiles, AD patients are likely at higher risk of hemorrhagic, but not ischemic stroke. </span></span></span></span></span></span></span></span></span></span></p>
Hunters' Willingness to Adopt and Support Biosecurity Actions to Prevent the Spread of Rabbit Hemorrhagic Disease
<p>These are the data published in Shapiro et al. "Engaging Stakeholders in Wildlife Disease Management: Hunters’ Willingness to Adopt and Support Biosecurity Actions to Prevent the Spread of Rabbit Hemorrhagic Disease" Conservation Science and Practice, published online on 12/22/22.</p> <p>Note: We uploaded the corrected dataset (Version 2) on 12/23/22. We found coding errors for the gender and age variables in the original data set (Version 1), which we corrected. The updated data set also contains a Case Number variable (which was randomly generated by SPSS) and the RHDV2 status of the state in which respondents resided at the time of the survey. This binary variable (0=no RHDV2; 1=RHDV2 cases) was calculated using people’s state, the date they took the survey, and the latest RHDV2 maps.</p>
Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Morphine
ClinicalTrials.gov study NCT04138615. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma
ClinicalTrials.gov study NCT02647515. IPD Sharing: YES. Countries: 0. Publications: 3.
Comparison of Endoscopic Injection of Conventional and Double Doses Cyanoacrylate for Gastric Variceal Hemorrhage
ClinicalTrials.gov study NCT00735358. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Does Cold Saline Used to Inflate a Balloon Tamponade Catheter More Significantly Reduce Blood Loss From Postpartum Hemorrhage Than Room Temperature Saline?
ClinicalTrials.gov study NCT02735733. IPD Sharing: NO. Countries: 0. Publications: 1.
External Validation of the Clinical Pre-hospital "Red- Flag" Alert for Activation of Intra-hospital Hemorrhage Control Response in Blunt Trauma.
ClinicalTrials.gov study NCT05820217. IPD Sharing: Not stated. Countries: 0. Publications: 13.
Stem Cell Therapy for Intracerebral Hemorrhage
ClinicalTrials.gov study NCT06862388. IPD Sharing: NO. Countries: 0. Publications: 13.
Ultra-early STatin in Patients With Aneurysmal subaRachnoid Hemorrhage (Ue-STAR)
ClinicalTrials.gov study NCT06559072. IPD Sharing: YES. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.